Dietary polyphenols regulate appetite mechanism via gut-brain axis and gut homeostasis
Japanese Press Release, Novo Nordisk, Jun 2020
Semaglutide works through multiple mechanisms: it acts as a glucagon-like peptide-1 (GLP-1) receptor agonist , stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system pathways
Furthermore, the BPC-157 research chemical has also proved useful when treating skin burns helping reduce scarring (2)
Serious adverse events are rare but include pituitary axis suppression with long-term high-dose use and worsening insulin resistance in patients with pre-existing glucose issues
Is there any clinical evidence that combining two GLP-1 medications improves weight loss